Adrienne G. Waks, MD, on breast cancer treatment | Dana-Farber Cancer Institute

Dr Waks on Ongoing Research in Residual HER2+ Breast CancerПодробнее

Navigating Decisions at the Intersection of Local and Systemic Management of Early Breast CancerПодробнее

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее

What Role Do Breast Cancer Patients Play in Care and Treatment Decisions?Подробнее

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast CancerПодробнее

Should Breast Cancer Patients Consider a Clinical Trial?Подробнее

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast CancerПодробнее

Research Update for HER2-Positive MBC | 2023-2024 EMBRACE MBC Virtual Forum SeriesПодробнее

Dr Waks on Unmet Needs in Patients With HER2+ Breast CancerПодробнее

How Is Metastatic Breast Cancer Treated?Подробнее

Hesitant to Join a Breast Cancer Clinical Trial? What You Should Know.Подробнее

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MDПодробнее

Metastatic Breast Cancer Forum 2018: Clinical Trials 101 | Dana-Farber Cancer InstituteПодробнее

2020 EMBRACE Metastatic Breast Cancer Virtual Forum Series | Research Update for ER-Positive MBCПодробнее

Study of preoperative treatment with nab-paclitaxel and pembrolizumab in HR+ breast cancerПодробнее

What Are the Treatment Options for Early Stage Breast Cancer?Подробнее

Why Should Breast Cancer Patients Feel Empowered to Speak Up About Their Care?Подробнее

Key Questions Patients Should Ask Before Participating in a Breast Cancer Clinical TrialПодробнее